

## CONTENTS

*This document is issued by our Company solely in connection with the [REDACTED] and the [REDACTED] and does not constitute an [REDACTED] to sell, or a solicitation of an [REDACTED] to subscribe to or buy, any security other than the [REDACTED] by this document pursuant to the [REDACTED]. This document may not be used for the purpose of and does not constitute an [REDACTED] to sell, or a solicitation of an [REDACTED] to subscribe to or buy, any security in any other jurisdiction or in any other circumstances. No action has been taken to permit a [REDACTED] of the [REDACTED], or the distribution of this document, in any jurisdiction other than Hong Kong. The distribution of this document and the [REDACTED] and sale of the [REDACTED] in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom. Information contained on our websites, located at [www.genscript.com](http://www.genscript.com) and [www.bestzyme.com](http://www.bestzyme.com), does not form part of this document.*

*You should rely only on the information contained in this document and the [REDACTED] to make your [REDACTED] decision. Our Company has not authorized anyone to provide you with information that is different from what is contained in this document. Any information or representation not made in this document must not be relied on by you as having been authorized by our Company, the [REDACTED], the Sole Sponsor, [REDACTED], the [REDACTED], any of their respective directors, officers, employees, agents or representatives or any other person involved in the [REDACTED].*

	<i>Page</i>
<b>Expected Timetable</b> .....	i
<b>Contents</b> .....	iii
<b>Summary</b> .....	1
<b>Definitions</b> .....	14
<b>Glossary of Technical Terms</b> .....	29
<b>Forward-looking Statements</b> .....	39
<b>Risk Factors</b> .....	40
<b>Waivers and Exemptions from Strict Compliance with the [REDACTED] Rules and Exemptions from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance</b> .....	76
<b>Information about This Document and the [REDACTED]</b> .....	82
<b>Directors and Parties Involved in the [REDACTED]</b> .....	86
<b>Corporate Information</b> .....	90
<b>Industry Overview</b> .....	92
<b>Regulations</b> .....	117
<b>History and Reorganization</b> .....	142
<b>Business</b> .....	164

## CONTENTS

	<i>Page</i>
<b>Relationship with Controlling Shareholders . . . . .</b>	240
<b>Directors and Senior Management . . . . .</b>	246
<b>Share Capital . . . . .</b>	260
<b>Substantial Shareholders . . . . .</b>	264
<b>Financial Information . . . . .</b>	267
<b>Future Plans and Use of Proceeds . . . . .</b>	329
<b>Underwriting . . . . .</b>	332
<b>Structure of the [REDACTED] . . . . .</b>	344
<b>How to Apply for Hong Kong [REDACTED] Shares . . . . .</b>	354
<b>Appendix I          Accountants’ Report . . . . .</b>	I-1
<b>Appendix II          Unaudited [REDACTED] Financial Information . . . . .</b>	II-1
<b>Appendix III          Property Valuation . . . . .</b>	III-1
<b>Appendix IV          Summary of the Constitution of Our Company and Cayman Islands Company Law . . . . .</b>	IV-1
<b>Appendix V          Statutory and General Information . . . . .</b>	V-1
<b>Appendix VI          Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection . . . . .</b>	VI-1